GlassScriptPhysician profile
Jessica L Borowicz
NPI 1477701357
$91,079.75
in general payments reported to CMS, 2019-2025
38 companies · $2,952 in 2025
The $2,952 reported for 2025 was more than what 84% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39K · 2020: $12K · 2021: $13K · 2022: $12K · 2023: $7,348 · 2024: $3,925 · 2025: $2,952.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,397 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,500 · Education: $328.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,396.77 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,500.00 |
| Education | $327.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $29,726.78 | 2019-2025 | Nemluvio, Aklief, Dysport |
| Celgene Corporation | $27,155.17 | 2019 | |
| Amgen INC. | $18,836.03 | 2019-2025 | Otezla, Otezla |
| Abbvie INC. | $3,381.22 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Janssen Biotech, INC. | $1,752.86 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Novartis Pharmaceuticals Corporation | $1,540.90 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,242.18 | 2019-2025 | Dupixent |
| Lilly USA, LLC | $1,206.82 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Sun Pharmaceutical Industries INC. | $953.43 | 2019-2025 | Winlevi, Ilumya |
| Genzyme Corporation | $867.19 | 2019-2025 | |
| Ucb, INC. | $610.08 | 2019-2025 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $542.62 | 2022-2025 | Sotyktu |
| Dermavant Sciences, INC. | $512.89 | 2023-2024 | Vtama |
| Pfizer INC. | $432.33 | 2019-2025 | |
| Botanix Sb INC | $336.05 | 2025 | Sofdra |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Borowicz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.